-

Agilent Early Career Professor Award Presented to Carl DeSelm

Washington University School of Medicine in St. Louis professor recognized for research in cellular immunotherapy

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Carl DeSelm, M.D., Ph.D., has received the 2020 Agilent Early Career Professor Award. Dr. DeSelm is an assistant professor of Radiation Oncology at the Washington University School of Medicine in St. Louis, MO. This years’ award topic is cellular engineering and analysis—a field that greatly impacts Agilent customers.

The DeSelm lab’s current research focuses on the engineering and clinical development of a new class of cell immunotherapy, engineering Antigen Presenting Cells (APC). This approach can address some of the limitations of the CAR T cell therapy in the treatment of solid tumors. There is also interest in understanding and leveraging the role that radiation treatment can have to synergize with CAR-APC immunotherapy.

"Carl is an outstanding young investigator, and we are thrilled for him to receive this prestigious award,” said Julie Schwarz, MD, Ph.D., professor and vice-chair of research in Washington University’s Department of Radiation Oncology. “Support from the Agilent Early Career Professor Award will allow Carl to grow and further develop his research program and explore new exciting applications of CAR cell engineering."

“Advances in cellular immunotherapy rely on the engineering (genome editing) and characterization of cell populations and the quality control of cells during large-scale amplification and delivery,” explained Jack Wenstrand, Ph.D., director of University Relations and External Research at Agilent. “By partnering with a leading young researcher in this important field, we continue our investment to support the development of better cell therapeutics products and solutions.”

Wenstrand stated that Dr. DeSelm was selected as the 2020 recipient because of his exceptional early-career contributions, strong publications, and compelling research plans in the field of cellular immunotherapy. Dr. DeSelm joined the Washington University faculty in June 2018 as an assistant professor of Radiation Oncology. His laboratory is part of the Bursky Center for Human Immunotherapy and Immunology Programs (CHiiPs), and he is a Bursky fellow at the School of Medicine. Dr. DeSelm earned his M.D. and Ph.D. from Washington University School of Medicine in 2012.

The Agilent Early Career Professor Award is an annual program that recognizes–and supports–promising research from professors who, early in their careers, show outstanding potential for future research in areas of importance to the communities Agilent serves. This award underscores Agilent's commitment to furthering research through the company's products and services, financial support, and collaborative engagement by Agilent scientists and engineers. Further information about the Agilent Early Career Professor Award is available at Agilent.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. In its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Media Contact
Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Media Contact
Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

More News From Agilent Technologies Inc.

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharm...

Agilent Announces Cash Dividend of 25.5 Cents per Share

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent’s board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global leader in analyti...

Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent’s inaugural Instrument Trade‑In Impact Award, recognizing exceptional sustainability leadership demonstrated through their participation in Agilent’s trade‑in and buyback program. The annual award honors the global partner that achieves the highest sustainability impact by diverting end‑of‑life laboratory instruments from landfill and con...
Back to Newsroom